Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06383689

Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring

The notion of genuine placebo effects on epileptic seizure events (i.e., effects beyond methodological study artifacts) is incompatible with the standard model of epilepsy seizure genesis. In this single-blind controlled study, the effectiveness of a covered placebo on (1) the timing of the occurrence of a first epileptic seizure ("seizure pill") versus (2) the subjective well-being ("comfort pill") during pre-surgical video-EEG monitoring will be examined. It is hypothesized that a placebo effect on subjective well-being can be demonstrated, but that epileptic seizure events are not influenced by placebo.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Patients undergoing long-term video-EEG monitoring for the purpose of pre-operative epilepsy diagnostics will be invited to participate in the study. Patients will be pseudo-randomized into three study conditions (in blocks of six). The study participants will take a placebo pill designated either as a "seizure pill" (Condition PCB-S) or a "comfort pill" (PCB-W) in addition to their regular medication in the morning and evening, or not receive any additional placebo medication (No-PCB).

Both the "seizure pill" and the "comfort pill" are commercially available, ingredient-free placebo pills (P-pills blue Lichtenstein, produced by Winthrop Pharmaceuticals). No further details about the composition of the pill will be provided; information about the ingredients of the respective pill will be provided after the end of the entire study. Depending on randomization, study participants will be informed that this pill is expected to (1) either facilitate/accelerate the occurrence of epileptic seizures (PCB-S) (thereby shortening the required time for video-EEG monitoring), or (2) to lead to a more stable/improved emotional well-being during the stay in the V-EEG (PCB-W) or (3) will not receive a pill but are asked to fill-in questionnaires and diaries like the other patients.Start of the V-EEG will be documented as the starting point for latency measurement for the occurrence of a first epileptic seizure. The patients will be pseudo-randomized into the three study conditions: Out of every 6 patients, 2 will be assigned to each of the three study conditions. Patients in both active study conditions will receive the first pill at the start of the V-EEG. After that, study participants will receive the respective "pill" morning and evening in addition to their other medications, however, visibly separated from them and clearly marked as study medication. All participants, including controls, will keep a seizure diary during the V-EEG. In addition, they will fill-in a newly constructed ad-hoc questionnaire at the beginning and after the V-EEG. Finally, all patients will be asked twice daily (around 9 AM and around 6 PM) about their overall emotional well-being using a visual analogue scale (VAS; 0 very bad ... 100 extremely good). The highly standardized clinical procedures of presurgical evaluation are in no way affected by the study. In particular, anti-seizure medications for all patients will be tapered off following exactly the same schedule without any influence from the study; the medication will be precisely documented.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • eligibility for presurgical epilepsy diagnostics

Exclusion criteria

  • inclusion criterion implies all exclusion criteria for this procedure
  • legal guardian
  • lack of consent or lack of capability to provide informed consent

Treatment and study plan

Seizure placebo pill

Other

patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG

Other names: PCB-S

Well-being placebo pill

Other

patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG

Other names: PCB-W

Primary outcomes

  1. Latency to first epileptic seizure

    Time frame: immediately after video-EEG monitoring

    temporal latency from beginning of the video-EEG monitoring to the occurrence of the first epileptic seizure

Secondary outcomes

  1. Occurrence of an epileptic seizure

    Time frame: immediately after video-EEG monitoring

    Occurrence of an epileptic seizure during the video-EEG (yes/no)

  2. Early occurrence of an epileptic seizure within the first 72 hours

    Time frame: immediately after video-EEG monitoring

    Early occurrence of an epileptic seizure within the first 72 hours of video-EEG monitoring (yes/no)

  3. Number of epileptic seizures during the video-EEG

    Time frame: immediately after video-EEG monitoring

    Total number of epileptic seizures which occurred during the video-EEG

  4. Number of early occurring epileptic seizures

    Time frame: 72 hours after video-EEG monitoring

    Total number of epileptic seizures recorded during the first 72 hours of video-EEG

  5. Daily average frequency of epileptic seizures

    Time frame: immediately after video-EEG monitoring

    Average daily frequency of epileptic seizures during the entire video-EEG (calculated)

  6. Very early first epileptic seizure

    Time frame: after 1st day after video-EEG monitoring

    First epileptic seizure on the first day of video-EEG (yes/no)

  7. Early epileptic seizure

    Time frame: after 2nd day after video-EEG monitoring

    First epileptic seizure on the first or second day of video-EEG (yes/no)

  8. Epileptic seizure within the first three days

    Time frame: after 3rd day after video-EEG monitoring

    First epileptic seizure within the first three days of video-EEG (yes/no).

  9. Emotional well-being

    Time frame: immediately after video-EEG monitoring

    Visual analogue scales (diary), 2x daily queries (9 am, 6 pm): mean and standard deviation (stability), during the video-EEG

  10. Dissociative non-epileptic seizures

    Time frame: immediately after video-EEG monitoring

    occurrence of dissociative non-epileptic seizures during video-EEG (yes/no)

Study contacts

Contact information is provided by the study sponsor or research team.

Christian Hoppe, PD Dr.

CONTACT

[email protected]

+49 228 287-16172

Rainer Surges, Prof.

CONTACT

[email protected]

+49 228 287-15727

Sponsors and collaborators

Lead sponsor

University Hospital, Bonn

Other

Registry information

Official study title

Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring (OPERA)

Acronym: OPERA

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Apr 25, 2024
Registry last updated
Jun 10, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.